Stephen Chin
LightNews LightNews
schinau.bsky.social
Stephen Chin
@schinau.bsky.social
230 followers 61 following 0 posts
#radonc in mainly GU, thoracic, lower GI & gyn ca. interests in palliative onc, #brachy, SABR, MR in RT
https://www.linkedin.com/in/stephenchin001
Posts Replies Media Videos
Reposted by Stephen Chin
achoud72.bsky.social
Our review on the promise of #radiotherapy in #NMIBC #Openaccess #WhereisHoskin @mcrcnews.bsky.social @oncoalert.bsky.social @southamptonctu.bsky.social #TRAINTrial
www.mdpi.com/2072-6694/17...
The Promise of Radiotherapy in High-Risk Non-Muscle Invasive Bladder Cancer
Global shortages, toxicities, and high levels of incomplete treatment with Bacillus Calmette Guerin (BCG) for non-muscle invasive bladder cancer has resulted in increasing interest in alternative trea...
www.mdpi.com
February 13, 2025 at 9:33 AM
Reposted by Stephen Chin
mguckenberger.bsky.social
Aiming to refine your #radonc in 2025 !

Offer RT for low-volume metastatic PC, only ?
What benefit of RT is to be communicated to pts & colleagues ?
How about SBRT or surgery ?

Virtual Grand Rounds in Radiation Oncology

Jan 8th / 17:00 - 17:30 CET
Dr Alberto Bossi

👇
www.usz.ch/veranstaltun...
January 2, 2025 at 9:27 AM
Reposted by Stephen Chin
oncoalert.bsky.social
Day Two of #BLADDR24
Dr Vérane Achard
BCa management in 2025
View of the radiation oncologist

Radiotherapy is no longer just an alternative to surgery but a key component

@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
November 28, 2024 at 9:27 AM
Reposted by Stephen Chin
achoud72.bsky.social
#WhereisHoskin appears on #BlueSky How to further personalise #radiotherapy
➡️ Bladder only unless N+
➡️ Give NAC if appropriate
➡️ Use a radiosensitiser, any radiosensitiser
➡️ There are compelling biomarkers, but need prospective qualification
#BLADDR24 @oncoalert.bsky.social
November 27, 2024 at 4:03 PM